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Abstract - Mesenchymal stem cells (MSCs) were isolated from human periodontal ligament (hPDL-MSCs) and character-
ized by their morphology, clonogenic efficiency, proliferation and differentiation capabilities. hPDL-MSCs, derived from 
normal impacted third molars, possessed all of the properties of MSC, including clonogenic ability, high proliferation 
rate and multi-lineage (osteogenic, chondrogenic, adipogenic, myogenic) differentiation potential. Moreover, hPDL-MSCs 
expressed a typical MSC epitope profile, being positive for mesenchymal cell markers (CD44H, CD90, CD105, CD73, 
CD29, Stro-1, fibronectin, vimentin, α-SMA), and negative for hematopoietic stem cell markers (CD34, CD11b, CD45, 
Glycophorin-CD235a). Additionally, hPDL-MSCs, as primitive and highly multipotent cells, showed high expression of 
embryonic markers (Nanog, Sox2, SSEA4). The data obtained provided yet further proof that cells with mesenchymal 
properties can be obtained from periodontal ligament tissue. Although these cells should be further investigated to de-
termine their clinical significance, hPDL-MSCs are believed to provide a renewable and promising cell source for new 
therapeutic strategies in the treatment of periodontal defects.
Key words: Periodontal ligament, mesenchymal stem cells, characterization, proliferation, differentiation, tissue regenera-
tion 
INTRODUCTION
Stem cells are defined as clonogenic cells capable 
of both self-renewal and multi-lineage differentia-
tion. Stem cells can be isolated in the earliest stages 
of embryogenesis (embryonic stem cells) or in dif-
ferent post-natal tissues (adult stem cells) including 
brain, bone marrow, skin, liver, heart, lungs, kidney 
and spleen. The most well-characterized source for 
adult stem cells is bone marrow, which beside he-
matopoietic stem cells, contains a subset of nonhe-
matopoietic stem cells, called marrow stromal stem 
cells (Owen, 1988) or mesenchymal stem cells (Cap-
lan, 1991), and more commonly now, mesenchymal 
stromal cells (MSCs) (Horwitz et al., 2005). These 
cells have the ability of self-renewal and can differ-
entiate into distinctive end-stage cell types of mes-
odermal lineages, including osteocytes, chondro-
cytes, adipocytes, muscle cells, bone marrow stroma 
and other connective tissues (Pittenger et al., 1999; 
Jiang et al., 2002; Lee et al., 2004). These properties 
make MSCs an ideal candidate cell type for tissue 
engineering and regenerative medicine treatment. 
In the past ten years, MSCs have been extensively 
used in many medical disciplines for the repair and/
or regeneration of defective tissues and organs such 
as bone (Horwitz et al., 2002), cartilage (Murphy et 
al., 2003), heart (Stamm et al., 2003) and spinal cord 
(Mezey et al. 2003). Except for bone marrow, MSCs 
were also found in almost all postnatal organs and 
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tissues, including adipose tissue, the periosteum, 
synovial membrane, synovial fluid, muscle, dermis, 
trabecular bone, infrapatellar fat pad, articular car-
tilage and umbilical cord blood (Bianco et al., 2008; 
Rebelatto et al., 2008).
The identification and isolation of dental mes-
enchymal stem cells such as dental pulp stem cells 
(DPSCs), stem cells from human exfoliated decidu-
ous teeth (SHED) and stem cells from apical papilla 
(SCAP) have opened up exciting possibilities for the 
application of tissue engineering as well as gene-based 
therapies in reconstructive dentistry (Rodriquez-
Lozano et al., 2011). Furthermore, a population of 
multipotent stem cells, termed periodontal ligament 
stem cells (PDLSCs), have been found in periodon-
tal ligament (PDL) (Seo et al., 2004). Beside their 
promising potential for therapeutical application in 
periodontal regeneration (Shi et al., 2005; Park et 
al., 2011), data suggest that the proper handling of 
PDLSCs is of great importance for their use in tissue 
engineering (Akizuki et al., 2005; Hasegawa et al., 
2005). In order to provide valuable insights regard-
ing their future use in periodontal regeneration, the 
aim of this study was to isolate MSCs from human 
periodontal ligament (hPDL-MSCs), also known as 
PDLSCs, and analyze their behavior in cell culture 
conditions. For this purpose, long-term cultures of 
hPDL-MSCs were established and the cells morphol-
ogy, clonogenic efficiency, proliferation rate, immu-
nophenotype and differentiation potential were de-
termined. 
MATERIALS AND METHODS
Tissue collection and hPDL-MSCs isolation
Normal impacted third molars were extracted for 
orthodontic purposes from 3 patients that were 18-
25 years old, at the Department of Oral Surgery of 
the Faculty of Dental Medicine, University of Bel-
grade, according to the approved ethical guidelines 
set by the Ethics Committee of the Faculty of Dental 
Medicine, University of Belgrade. Immediately after 
extraction, the periodontal ligament was gently sepa-
rated from the middle third of the tooth root sur-
face, minced into small peaces, transferred to a 25 
cm2 flask with Dulbecco’s modified Eagle’s medium 
(DMEM; PAA Laboratories, Pasching, Austria) sup-
plemented with 10% fetal bovine serum (FBS; PAA 
Laboratories), 100 U/ml penicillin and 100 μg/ml 
streptomycin (PAA Laboratories), and cultured at 
37°C in a humidified atmosphere containing 5% CO2 
with medium exchange. Adherent cells that mor-
phologically resembled characterized MSCs, as pre-
viously described (Seo et al., 2004), could be seen as 
early as 4 days post-plating, while approximately af-
ter 7 days, the first colonies were observed. After 3-4 
weeks of culture, when the 80% to 90% confluence 
was reached, the cells were detached by using 0.05% 
trypsin with 1 mM EDTA (PAA Laboratories) and 
the remnants of the tissue fragments were removed. 
Following the first confluence (P0) cells, the cells 
were passaged regularly in growth medium (GM – 
DMEM with 10% FBS). For this study, in all experi-
ments cells from third to sixth passages were used.
Colony-Forming Units-Fibroblastic (CFU-F) and cell 
growth assays
CFU-F assays were performed by plating hPDL-
MSCs in 6-well plates at 100, 500 and 1000 cells/
well in GM in two replicas. After 10 days in culture 
at 37°C in a humidified atmosphere containing 5% 
CO2, the cells were washed with Dulbecco’s phos-
phate buffered saline (PBS; PAA Laboratories), fixed 
with ice-cold methanol and stained with 0.3% crystal 
violet. The number of visible colonies (comprising of 
more than 50 cells) was determined and the colony 
forming efficiency calculated as the percentage of the 
seeded cells that formed colonies. 
Cell growth assay was performed by seeding 
hPDL-MSCs in GM in triplicate in 96-well plates at 
5×103 cells/well. After 8 days, the cells were detached 
and counted by the Trypan blue exclusion test. The 
population doubling times (PDT) were calculated 
according to the formula PDT=(T–T0) lg2/(lgNt–
lgN0), where T0 is the starting time and T is the end-
ing time of the cell culture, while N0 and Nt respec-
tively represent the number of seeded and harvested 
cells.
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Flow cytometry analysis
The mesenchymal stromal phenotype of isolated and 
in vitro-expanded periodontal cells was determined 
by flow cytometry analysis for expression of positive 
(CD44H, CD90 – Thy-1/Thy-1.1, CD105 – endog-
lin, CD 73 – ecto-5’-nucleotidase and CD 29 integrin 
beta1) and negative (CD45 – leukocyte common 
antigen/cell marker of hematopoietic origin, CD34 
– hematopoietic progenitor cell antigen, CD11b – 
Mac-1 α, CD235a – glycophorin A) MSC markers. 
After harvesting with 1 mM EDTA for 10 min, the 
cells were washed in cold PBS supplemented with 
0.5% bovine serum albumin (BSA; Sigma-Aldrich, 
Saint Louis, MO, USA), and aliquots of 2 × 105 cells 
were labeled (30 min in the dark at 4oC) with mono-
clonal antibodies specific for human markers asso-
ciated with mesenchymal and hematopoietic line-
ages including anti-CD34-PE (Dako Cytomation, 
Glostrup, Denmark), anti-CD11b-FITC (Biosource, 
Camarillo, CA), anti-CD105-R-PE, anti-CD29-PE 
(Invitrogen), anti-CD45-FITC, anti-CD235a-PE, 
anti-CD90-PE, CD44H-PE, anti-CD73-PE (all from 
R&D Systems, Minneapolis, MN, USA). For the em-
bryonic stem cell (ESC) markers expression analyses, 
aliquots of 2×105 cells were fixed in formaldehyde 
and permeabilized in 90% methanol. Afterwards, 
MSCs were labeled with primary antibody for SOX2, 
SSEA4 and NANOG and with secondary FITC con-
jugated antibody (all purchased from R&D). The 
level of nonspecific binding was determined by using 
the appropriate FITC- and PE-conjugated isotype 
control antibodies (R&D Systems). Flow cytometry 
was performed using a CyFlow SL flow cytometer 
(Partec, Münster, Germany). 
Immunocytochemical analysis
For the immunocytochemical analysis, hPDL-MSCs 
were seeded over rounded coverslips and cultured for 
24 h in GM. After being fixed with 4% formaldehyde, 
cells were treated with PBS-0.1% Triton X for 2 min 
for cell membrane permeabilization, and then incu-
bated (1 h, room temperature) with primary mouse 
antibodies against vimentin (Santa Cruz Biotech, 
Santa Cruz, CA, USA), α-SMA (Sigma-Aldrich, St. 
Louis, MO, USA), fibronectin (Chemicon, Temecu-
la, CA, USA), and Stro-1 (R&D Systems), followed 
by incubation (1 h in the dark) with corresponding 
FITC-labeled secondary antibody and nuclear dye 
DAPI (Sigma-Aldrich) to counterstain. The samples 
were analyzed and photographed using an Axioskop 
2 plus epifluorescence microscope and AxioCam 
MRc5 camera (Carl Zeiss GmbH, Göttingen, Ger-
many).
Multilineage differentiation
To determine the differentiation potential of hPDL-
MSCs, cells were seeded in a 24-well plate (2×104 cells 
per well) cultured in GM until reaching subconfluent 
stage. At that point, GM was replaced with specific 
differentiation medium in order to induce differenti-
ation into diverse mesenchymal lineages, while cells 
cultured in GM only were utilized as controls. Cells 
were photographed using a light microscope with a 
digital camera.
To induce osteogenic differentiation, cells were 
cultured in DMEM supplemented with 10% FBS, 
100 U/ml penicillin, 100 μg/ml streptomycin, 10 
nM dexamethasone (AppliChem), 200 μM ascor-
bic acid-2-phosphate (Sigma-Aldrich), and 10 mM 
β-glycerophosphate (Sigma-Aldrich), and the media 
were replaced three times a week. On day 7, osteo-
genic differentiation was analyzed via assessment of 
alkaline phosphatase (ALP) activity by staining with 
5-bromo-4-chloro-3-indolyl phosphate/nitro blue 
tetrazolium, BCIP/NBT (Sigma–Aldrich, Saint Lou-
is, MO, USA). Visualization of calcium deposition 
and extracellular matrix mineralization was obtained 
by Alizarin red staining assay performed after three 
weeks of osteogenic treatment.
Chondrogenic medium containing DMEM 
supplemented with 2 ng/ml transforming growth 
factor-β1 (TGF-β1; R & D Systems, Minneapolis, 
MN, USA), 200 μM ascorbic acid-2-phosphate, 10 
nM dexamethasone, 100 U/ml penicillin/streptomy-
cin and 5% FBS was used to induce chondrogenic 
differentiation. The cultures were incubated for 21 
days and at the end of the incubation, chondrogenic 
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differentiation of the cells was assessed via staining 
with Safranin O (Merck, Darmstadt, Germany).
For adipogenic differentiation, subconfluent 
hPDL-MSCs were cultured in DMEM supplement-
ed with 10% FBS, 100 U/ml penicillin, 100 μg/ml 
streptomycin, 100 μg/ml isobutyl-methylxanthine 
(IBMX; Sigma-Aldrich), 1 μM dexamethasone, and 
10 μg/ml insulin (Actrapid; Novonordisc, Bagsvaerd, 
Denmark) for three weeks. The presence of intrac-
ellular lipid droplets, as an indicator of adipogenic 
differentiation, was confirmed by Oil Red O (Merck 
Chemicals, Darmstadt, Germany) staining. 
To induce myogenic differentiation, hPDL-MSCs 
were cultured in DMEM supplemented with 5% 
horse serum (PAA Laboratories), 2% FBS, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 50 μM hydrocor-
tisone (Galenika, Beograd, Serbia) and 0.1 μM dex-
amethasone. After 3 weeks, the cells were fixed with 
ice-cold methanol, stained with 0.3% crystal violet 
and examined for the presence of myotubes contain-
ing three or more aligned nuclei. 
RESULTS
Growth characteristics of hPDL-MSCs
MSCs were successfully isolated from the alveolar 
crestal and horizontal fibers of human periodontal 
ligament and characterized following the minimal 
criteria for defining MSCs (Dominici et al. 2006). 
First, the ability of hPDL-MSCs to grow as spindle-
shape fibroblast-like, plastic-adherent cells that give 
rise to CFU-F colonies was demonstrated (Fig. 1). 
Namely, after 4 days in culture, flattened cells at-
tached to the culture flasks displaying a fibroblast-
like, spindle-shaped morphology (Fig. 1A). These 
cells gradually grew to form small colonies (Fig. 
1B), while the confluence was reached within 7-10 
days. No spontaneous differentiation was observed 
throughout the passages. 
Results of CFU-F assay evidenced the clonogenic 
potential of hPDL-MSCs expanded in culture. How-
ever, the clonogenic efficiency of hPDL-MSCs was 
low since 5.75 and 29.25 colonies were generated 
from 100 or 1000 plated cells, respectively (Table 1). 
In addition, a decrease in CFU-F frequencies was ob-
served as the initial plating density was increased.
Analysis of hPDL-MSC proliferation in the cell 
growth assay showed that the cell numbers of hPDL-
MSCs increased to about 6-fold at day 8 after plating 
(5x103 cells on day 0 up to 2.95±1.8 x104 cells on day 
8), while calculated PDT values were approximately 
48 h for 5x103 cells plated.
Phenotypic properties of hPDL-MSCs
Studies performed to characterize the phenotype 
of the hPDL-MSC comprise usage of a large panel 
of antibodies specific to known antigens associated 
with human mesenchymal and hematopoietic line-
ages. The flow cytometry analyses revealed a high 
expression of surface markers related to MSCs, such 
as CD44 (77.90-94.47% positive cells), CD90 (70.35-
77.14% positive cells), CD105 (74.98-94.00% positive 
cells), CD73 (92.71-97.45% positive cells) and CD29 
(78.73-98.06% positive cells), as shown in Fig. 2A. As 
expected, the hPDL-MSCs were negative for hemat-
opoietic stem cell markers, since less than 2% cells 
expressed CD34, CD11b, CD45 or CD235a antigen 
(Fig. 2B). At the same time, immunocytochemical 
staining of the cells demonstrated that the hPDL-
MSCs were also positive for the additional mesen-
chymal cell markers, including Stro-1, fibronectin, 
vimentin and α-SMA (Fig. 3). Using flow cytometry, 
we further investigated whether hPDL-MSCs display 
embryonic stem cell characteristics. Representative 
histograms shown in Fig. 4 demonstrate that a large 
fraction of these cells express embryonic stem cell-
associated antigens, such as Nanog, Sox2 and SSEA4. 
The higher percentage of positive cells was revealed 
for the Nanog molecule (85.49-93.99%) then for the 
Sox2 marker (73.55-80.17% positive cells), while the 
number of positive cells ranged from 29.85 to 56.09% 
for SSEA4 antigen.
Differentiation potential of hPDL-MSCs
As a functional assay to confirm the MSCs iden-
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fig. 1. Morphological and growth characteristics of hPDL-MSCs. (A) Phase-contrast microscopy showing flattened, fibroblast-like 
morphology of hPDL-MSCs after 4 days in culture. Scale bar: 25 μm. (B) Single-cell-derived colony stained with crystal violet after 10 
days in culture. Scale bar: 100 μm. (c) CFU-F assay. Clonogenic colonies originating from a single cell after 10 days cultivation in GM 
stained with crystal violet. 
fig. 2. Immunophenotypic characteristics of hPDL-MSCs. Representative flow cytometry histograms showing the expression (empty 
histograms) of: (A) selected mesenchymal markers (CD44H, CD90, CD105, CD73, CD29) and (B) hematopoietic markers (CD34, 
CD45, CD11b, CD235a) by hPDL-MSCs, with percentages of positive cells based on the isotype controls (shaded histograms). 
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tity, we next examined the differentiation potential 
of hPDL-MSCs and demonstrated their osteogenic, 
adipogenic and myogenic differentiation capacity. 
The osteoblast differentiation capacity was de-
termined by staining the cells for ALP activity after 
7-day incubation in osteogenic differentiation me-
dium along with standard culture medium as con-
trol. Obtained results confirmed the osteogenic dif-
ferentiation potential of hPDL-MSCs since a notably 
increased ALP activity was observed in hPDL-MSC 
cultures incubated in osteogenic differentiation me-
dium compared with cells exposed to regular growth 
medium (Fig. 5A). In addition, 3-week-old cultures 
of hPDL-MSCs incubated in an osteoinductive me-
dium demonstrated the capacity to form Alizarin 
red positive condensed nodules, confirming that 
these deposits as calcium mineralized matrix, which 
is indicative of osteoblasts (Fig. 5B). In the control 
cultures, these were not observed. 
Chondrogenic differentiation was determined by 
staining of the secreted cartilage-specific proteogly-
cans with Safranin O. In hPDL-MSCs grown under 
chondrogenic conditions for 21 days, the presence of 
chondrogenic proteoglycans was observed by posi-
tive Safranin O staining, confirming chondrogenic 
differentiation (Fig. 5C). As expected, control cul-
tures grown in regular medium were negative for Sa-
franin O staining.
Adipogenic induction was evidenced by the ac-
cumulation of lipid-rich vacuoles within the hPDL-
MSCs cultured 21 days in adipogenic differentiation 
medium. The presence of intracellular lipid droplets 
was confirmed with Oil Red O staining, while in 
control culture conditions Oil Red O staining was all 
negative (Fig. 5D). 
The myogenic differentiation capacity of hPDL-
MSCs was demonstrated by the presence of multi-
nucleated myotubes observed after 16 days of hPDL-
MSC incubation in myogenic differentiation me-
dium, while in control cultures incubated in regular 
growth medium these were not seen (Fig. 5E). 
DISCUSSION
The PDL is a specialized, highly vascularized, con-
nective tissue encompassing the root of the tooth. Be-
side the role in maintaining tooth attachment to the 
surrounding alveolar bone, PDL possess a regenera-
tive capacity. Potential use of these cells in cell-based 
therapy for the treatment of damaged periodontia has 
encouraged researchers to identify PDL-МSCs and 
explore their characteristics. However, several stud-
fig. 3. Representative panels of immunocytochemical detec-
tion of mesenchymal markers, STRO-1, fibronectin, vimentin, 
and α−SMA on hPDL-MSCs. Cells were immunostained with 
indicated primary antibodies and corresponding FITC-labeled 
secondary antibodies (green). Cell nuclei were counterstained 
with DAPI (blue). The samples were analyzed and photographed 
using an epifluorescence microscope. Scale bars: 25 μm.
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ies indicated that appropriate manipulation of PDL-
MSCs is indispensable for their use in tissue engi-
neering (Akizuki et al., 2005; Hasegawa et al., 2005). 
In the present study, we give evidence that cells iso-
lated from human periodontal ligament tissue in our 
laboratory satisfy the criteria used to define multipo-
tent mesenchymal stem cells comparable to the fea-
tures of other postnatal MSCs isolated from various 
sources (Dominici et al., 2006), as well as of the hP-
DL-MSCs reported in previous studies (Nagatomo 
et al., 2006; Iwata et al., 2010). Namely, hPDL-MSCs 
isolated in this study showed the property to adhere 
to plastic as spindle-shape fibroblast-like cells when 
maintained in standard culture conditions. In addi-
tion, obtained hPDL-MSCs exhibited the ability to 
proliferate and to produce colonies from a single cell. 
By using a colony-forming efficiency assay that de-
termines the CFU-F number, we demonstrated that 
a minor population within the human periodontal 
ligament is clonogenic, being in agreement with pre-
vious observations made by other authors (Seo et al., 
2004). Furthermore, for hPDL-MSCs obtained in 
this study we demonstrated a high proliferation rate 
that could be ascribed to the developmental stage of 
the tissue used. In terms of potential application of 
hPDL-MSCs in cell-mediated therapies, it is a very 
important finding that no changes in their prolifera-
tion rate were observed throughout the passages.
To confirm stem cell properties of isolated and 
culture-expanded hPDL-MSCs, immunopheno-
type analyses of specific markers expression were 
performed by flow cytometry. As expected, for the 
obtained hPDL-MSCs a high rate of positivity (70%-
90%) was demonstrated for the typical mesenchy-
mal stem cell marker proteins, such CD44H, CD90, 
CD105, CD73 and CD92. Additionally, the results 
confirmed the absence of hematopoietic markers, 
fig. 4. Embryonic stem cell marker expression in hPDL-MSCs. Representative flow cytometry histograms show the expression of em-
bryonic antigens (NANOG, SOX2 and SSEA4) by hPDL-MSCs compared to isotype controls (solid histograms). Open histograms show 
specific staining for the indicated marker. The percentages represent the fraction of cells expressing each antigen.
table 1.  The frequency of colony-forming cells from periodontal tissue at different plating densities. 
PDL MSCs seeded CFU-F number Colony forming efficiency (%)
100  5,75 ± 3,86 5,75 ± 3,89
500 16,25 ± 5,56 3,25 ± 1,34
1000 29,25 ± 9,22 2,29 ± 0,46
Human PDL-MSCs were cultivated at density of 100, 500 or 1000 cells/well in GM for 10 days and stained for CFU-F. The results are 
presented as mean ± SD for three experiments; each performed in duplicate.
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such as CD34, CD11b, CD45 and Glycophorin-
CD235a, on tested cells. Moreover, hPDL-MSCs 
expressed the early mesenchymal stem cell surface 
marker, Stro-1, as well as fibronectin, vimentin and 
α-SMA, intracellular markers that are additional 
indicators of the mesenchymal origin of the cells, 
fig. 5. Multilineage differentiation potential of hPDL-MSCs. (A) Osteogenic differentiation was confirmed by positive staining for ALP 
activity; (B) Osteogenesis was evaluated by positive staining of extracellular matrix mineralization with Alizarin red; (C) Positive stain-
ing of proteoglycans by Safranin O confirmed chondrogenic differentiation of MSCs; (D) Oil Red O staining of intracytoplasmatic lipid 
droplets demonstrated adipogenic differentiation; (E) Myogenic diferentiation characterised by the formation of myotubes stained with 
crystal violet. Scale bars: 50 μm.
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which is in agreement with previous findings (Gay 
et al., 2007). Furthermore, we extended the charac-
terization of hPDL-MSCs by analyzing their expres-
sion profile for Nanog, Sox2 and SSEA4, embryonic 
stem cell markers, well known as key regulators of 
ESC self-renewal and pluripotency, The flow cytom-
etry results showing that hPDL-MSCs were strongly 
positive (more then 70%) for Nanog and Sox2, with 
a considerable proportion (30-50%) of hPDL-MSCs 
positive for the SSEA4 antigen, suggesting that the 
obtained hPDL-MSCs are primitive and highly 
multipotent cells. The expression of Nanog, Sox2 and 
SSEA4 in hPDL-MSCs analyzed in our study is in 
agreement with reports that human adult MSCs de-
rived from different sources may express ESC mark-
ers (Riekstina et al., 2009), as well as with previous 
findings of positive ESC marker expression in PDL-
MSCs (Huang et al., 2009; Trubiani et al., 2010).
However, as the final, most relevant criterion 
to confirm the stem cell nature of isolated hPDL-
MSCs, we analyzed their multilineage mesenchymal 
differentiation capacity. By the use of specific dif-
ferentiation media, we successfully demonstrated 
their multipotent nature, as these cells were able to 
differentiate into distinct mesenchymal cell lineages, 
including osteogenic, chondrogenic, adipogenic and 
myogenic lineages. In this way, we provided evidence 
that PDL contains cells that are clonogenic, highly 
proliferative and multipotent, pointing to their capa-
bility to regenerate the PDL tissue. 
Stem cell therapy is a novel and promising op-
tion for periodontal tissue regeneration. Periodonti-
tis is one of the most prevalent oral diseases in adults 
that leads to the destruction of periodontal tissues 
caused by pathogenic microflora in the dental plaque 
(Savage et al., 2009). This microbial community, as a 
highly organized bacterial biofilm, is resistant to both 
the applied antimicrobial agents and the host defense 
mechanisms (Armitage and Robertson, 2009). Bac-
terial infection induces an inflammatory response of 
the alveolar bone and soft periodontal tissues and the 
inflammation cascade often leads to irreversible de-
struction of tooth-supporting tissue and finally caus-
es tooth loss (Pihlstrom et al., 2005). Regeneration 
of lost periodontal tissues due to periodontitis has 
always been the ultimate goal of periodontal therapy. 
Current regenerative procedures, such as root surface 
conditioning, guided tissue regeneration, use of bone 
replacement grafts, application of exogenous growth 
factors or proteins, can only partially regenerate 
periodontal tissues (Chen et al., 2010). On the other 
hand, several studies demonstrated that transplanted 
autologous PDL-MSCs enhanced the regeneration 
of periodontal tissue in experimental defect models 
in animals, as well as in human patients with intrab-
ony defects, suggesting that PDL-MSCs transplanta-
tion may be an efficient alternative for the treatment 
of periodontitis (Kim et al., 2009; Ding et al., 2010; 
Feng et al., 2010).
In summary, we isolated, expanded and charac-
terized hPDL-MSCs, a population of stem cells that 
express specific mesenchymal cell markers and pos-
sess the ability to self-renew and differentiate into 
osteogenic, chondrogenic, adipogenic and myogenic 
cells. The data presented suggest that the obtained 
hPDL-MSCs can be easily accessible as a potential 
source for tissue engineering. However, further ex-
tensive studies need to be performed in order to 
better define PDL-MSC function in the process of 
regeneration in vivo, as well as to create suitable scaf-
folds for periodontium regeneration, with the ulti-
mate goal to develop and optimize new therapeutic 
strategies in periodontal defects.
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